Literature DB >> 21468784

Selective sentinel lymph node dissection for melanoma: importance of harvesting nodes with lower radioactive counts without the need for blue dye.

Liang-Chih Liu1, Brian M Parrett, Tyler Jenkins, Wayne Lee, Eugene Morita, Patrick Treseler, Laura Huang, Suresh Thummala, Robert E Allen, Mohammed Kashani-Sabet, Stanley P L Leong.   

Abstract

BACKGROUND: Determining how many sentinel lymph nodes (SLNs) should be removed for melanoma is important. The purpose of this study is to determine the frequency at which nodes that are less radioactive than the "hottest" node (which is negative) are positive for melanoma, how low of a radioactivity should warrant harvest, and if isosulfan blue is necessary.
METHODS: We reviewed 1,152 melanoma patients who underwent lymphoscintigraphy with technetium, with or without blue dye, and SLN dissection from 1996 to 2008. SLNs with radioactivity ≥10% of the "hottest" SLN, all blue nodes, and all suspicious nodes were removed and analyzed. The miss rate was calculated as the proportion of node positive cases in which the "hottest" SLN was negative.
RESULTS: SLNs were identified in 1,520 nodal basins in 1,152 patients. SLN micrometastases were detected in 218 basins (14%) in 204 patients (18%). In 16% of SLN-positive patients (33/204 patients), the positive SLN was found to have a lower radioactive count than the "hottest" SLN, which was negative. In 21 of these cases, the positive SLNs had radioactivity ≤50% of the "hottest" SLN. The 10% rule significantly reduced the miss rate to 2.5% compared with removal of only the "hottest" SLN (miss rate = 16%). Also, blue dye did not significantly decrease the miss rate compared with radiocolloid alone using the 10% rule.
CONCLUSIONS: To decrease the miss rate, all SLNs with ≥10% of the ex vivo radioactivity of the "hottest" SLN should be removed and blue dye is not essential.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21468784     DOI: 10.1245/s10434-011-1689-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

1.  Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database.

Authors:  Richard L White; Gregory D Ayers; Virginia H Stell; Shouluan Ding; Jeffrey E Gershenwald; Jonathan C Salo; Barbara A Pockaj; Richard Essner; Mark Faries; Kim James Charney; Eli Avisar; Axel Hauschild; Friederike Egberts; Bruce J Averbook; Carlos A Garberoglio; John T Vetto; Merrick I Ross; David Chu; Vijay Trisal; Harald Hoekstra; Eric Whitman; Harold J Wanebo; Daniel Debonis; Michael Vezeridis; Aaron Chevinsky; Mohammed Kashani-Sabet; Yu Shyr; Lynne Berry; Zhiguo Zhao; Seng-Jaw Soong; Stanley P L Leong
Journal:  Ann Surg Oncol       Date:  2011-06-07       Impact factor: 5.344

Review 2.  Clinical utilities and biological characteristics of melanoma sentinel lymph nodes.

Authors:  Dale Han; Daniel C Thomas; Jonathan S Zager; Barbara Pockaj; Richard L White; Stanley Pl Leong
Journal:  World J Clin Oncol       Date:  2016-04-10

3.  Localization of the Sentinel Lymph Node in Melanoma Without Blue Dye.

Authors:  Yinin Hu; Patrick D Melmer; Craig L Slingluff
Journal:  Ann Surg       Date:  2016-03       Impact factor: 12.969

4.  Limitation of indocyanine green fluorescence in identifying sentinel lymph node prior to skin incision in cutaneous melanoma.

Authors:  Kenjiro Namikawa; Arata Tsutsumida; Ryota Tanaka; Junji Kato; Naoya Yamazaki
Journal:  Int J Clin Oncol       Date:  2013-02-01       Impact factor: 3.402

5.  Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma.

Authors:  Vernon K Sondak; Dennis W King; Jonathan S Zager; Schlomo Schneebaum; Julian Kim; Stanley P L Leong; Mark B Faries; Bruce J Averbook; Steve R Martinez; Christopher A Puleo; Jane L Messina; Lori Christman; Anne M Wallace
Journal:  Ann Surg Oncol       Date:  2012-10-03       Impact factor: 5.344

6.  Redefining Criteria to Ensure Adequate Sentinel Lymph Node Biopsy With Dual Tracer for Breast Cancer.

Authors:  Li Xu; Jiqiao Yang; Zhenggui Du; Faqing Liang; Yanyan Xie; Quanyi Long; Jie Chen; Helin Zeng; Qing Lv
Journal:  Front Oncol       Date:  2020-12-03       Impact factor: 6.244

Review 7.  Detection of melanoma, breast cancer and head and neck squamous cell cancer sentinel lymph nodes by Tc-99m Tilmanocept (Lymphoseek®).

Authors:  Stanley P Leong
Journal:  Clin Exp Metastasis       Date:  2021-12-28       Impact factor: 5.150

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.